Actions
Pages
Subscribe for newsletter
Stories
Balaji Srinivasan, the former CTO of Coinbase, has unveiled the Balaji Fund, an investment venture targeting startup societies and 'Network States'. This fund focuses on emerging sectors such as crypto/Web3, AR/VR, and genomics, and is supported by Silicon Valley billionaires, including Brian Armstrong.
Balaji has proved to be ahead of the curve on several defining technology trends including Bitcoin so he’s worth paying attention to. He’s digging in on the intersection of crypto and real world organization. It will be fascinating to see his thesis on 'Network States' and the emergence of the “Grey Tribe” and how they find a way to politically connect in the real world connected with technology. Balaji opening up a fund and democratizing access in and of itself is a signal and represents a daring expansion of the tech investment narrative beyond conventional boundaries.
The Balaji Fund may catalyze a new era of decentralized, tech-driven societies, potentially revolutionizing how communities and governance function. The fund's unique focus on Bitcoin-driven 'Network States' challenges conventional tech investment paradigms, proposing a novel approach to societal organization and governance.
Srinivasan's decade-long work with the concept of 'Network States', rooted in decentralization and powered by Bitcoin, challenges traditional notions of governance, advocating for decentralized, tech-driven societies.
Story
The Multidisciplinary Association for Psychedelic Studies (MAPS) has submitted its application to the FDA for the approval of MDMA-assisted therapy for patients with PTSD.
This marks a significant moment in psychedelic research for therapeutic use following 30 years of clinical research. The anticipation of MDMA's regulatory approval reflects a growing understanding of its therapeutic benefits, challenging long-held stigmas associated with psychedelic drugs.
MAPS’ MDMA application could see FDA approval by August with priority review. The organization’s goal is to explore the therapeutic potential of MDMA in areas where effective treatments are currently limited, with a particular emphasis on disorders that disproportionately affect women.
Founded in 1986, MAPS initiated its first clinical trial involving MDMA for PTSD in 2004. The MAPS Public Benefit Organization, focused on FDA approval, was launched in 2014.
Story
The European Union announced an additional €3 billion fund to add to their plan to rapidly accelerate its battery manufacturing capabilities, positioning itself as a key player in the global EV revolution and advancing towards energy independence and sustainability.
Europe's battery industry was on a trajectory to not only meet but exceed its current demand, with projections suggesting self-sufficiency by 2027. But the pandemic and Russian invasion of Ukraine added friction to the plan. This new $3 billion investment hopes to put things back on track.
This funding and the surge in gigafactory projects represent Europe's strategic pivot towards reducing dependency on imports for critical battery materials, aiming to fortify its economic and technological sovereignty. The EU’s strategic investments and industrial strategy includes over 50 gigafactory projects, reshaping global trade and power structures.
Story
Innovators
Scroll
Open
Close